TGRX-678 Chinese Phase I in Chronic Myelogenous Leukemia (CML) Patients
Clinical trial NCT05434312 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT05434312
- Sponsor
- Shenzhen TargetRx Co., Ltd.
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2021-03-29
- Primary completion
- 2026-03-01
- Enrollment
- 90
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.